Mizuho Issues Positive Forecast for Relmada Therapeutics (NASDAQ:RLMD) Stock Price

Relmada Therapeutics (NASDAQ:RLMD) had its price target increased by Mizuho from $10.00 to $19.00 in a research report sent to investors on Friday morning,Benzinga reports. Mizuho currently has an outperform rating on the stock.

Other analysts have also recently issued research reports about the stock. Zacks Research upgraded shares of Relmada Therapeutics to a “hold” rating in a research note on Tuesday, January 27th. Lucid Cap Mkts raised shares of Relmada Therapeutics to a “strong-buy” rating in a report on Monday, March 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of Relmada Therapeutics in a research report on Wednesday, January 28th. Jefferies Financial Group initiated coverage on Relmada Therapeutics in a report on Monday, December 22nd. They issued a “buy” rating and a $9.00 price objective on the stock. Finally, Leerink Partners upgraded Relmada Therapeutics from a “market perform” rating to an “outperform” rating and set a $8.00 target price on the stock in a research report on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Relmada Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

Relmada Therapeutics Price Performance

Relmada Therapeutics stock opened at $6.07 on Friday. Relmada Therapeutics has a 12 month low of $0.24 and a 12 month high of $7.51. The business has a 50 day simple moving average of $4.50 and a 200-day simple moving average of $3.56. The stock has a market capitalization of $445.14 million, a PE ratio of -4.19 and a beta of 0.72.

Relmada Therapeutics (NASDAQ:RLMD) last posted its quarterly earnings data on Thursday, March 19th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.13). As a group, equities research analysts anticipate that Relmada Therapeutics will post -2.73 EPS for the current year.

Institutional Trading of Relmada Therapeutics

Several large investors have recently modified their holdings of the business. XTX Topco Ltd acquired a new position in shares of Relmada Therapeutics during the 2nd quarter worth approximately $28,000. Goldman Sachs Group Inc. purchased a new stake in Relmada Therapeutics in the 1st quarter valued at approximately $33,000. LMR Partners LLP acquired a new stake in Relmada Therapeutics during the 2nd quarter valued at $33,000. Schonfeld Strategic Advisors LLC acquired a new stake in Relmada Therapeutics during the 4th quarter valued at $64,000. Finally, Jane Street Group LLC purchased a new position in Relmada Therapeutics during the second quarter worth $69,000. 45.24% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Relmada Therapeutics

Here are the key news stories impacting Relmada Therapeutics this week:

• Positive Sentiment: Mizuho raised its price target sharply to $19 and upgraded RLMD to “Outperform,” implying large upside from current levels — this is a clear buy-side catalyst that can drive buying interest and re-rate sentiment. Read More.
• Positive Sentiment: Company press release highlights audited Q4 and full‑year 2025 results and a corporate update describing “significant progress across its pipeline” (ongoing clinical and strategic milestones). Pipeline advancement tends to support longer-term valuation for clinical-stage biotech. Read More.
• Neutral Sentiment: Earnings call transcripts and highlights from multiple outlets provide management commentary on strategy, program timelines and cash runway; useful for investors parsing catalysts but not an immediate market mover on their own. Review the call transcript for details on enrollment, milestones and guidance. Read More.
• Negative Sentiment: Relmada reported Q4 EPS of ($0.27), missing consensus (~($0.14)) by ~$0.13 — a near-term negative that highlights continued operating losses and may pressure sentiment until clearer revenue or milestone offsets emerge. Read More.

About Relmada Therapeutics

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.